title: The landscape of new drugs in lymphoma.
abstract: The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.
authors.affiliation: Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.affiliation: Division of Haematology, Mayo Clinic, 200 1st St Sw, Rochester, Minnesota 55905, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Ansell
authors.affiliation: Department of Lymphoma and Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
authors.forename: Nathan
authors.initials: N
authors.lastname: Fowler
authors.affiliation: Lymphoid Malignancies Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA.
authors.forename: Wyndham
authors.initials: W
authors.lastname: Wilson
authors.affiliation: Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, California 90404, USA.
authors.forename: Sven
authors.initials: S
authors.lastname: de Vos
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, A'Beckett Street, East Melbourne, Victoria 8006, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Seymour
authors.affiliation: Division of Oncology, Stanford University Cancer Center, 875 Blake Wilbur Drive, Stanford, California 94305, USA.
authors.forename: Ranjana
authors.initials: R
authors.lastname: Advani
authors.affiliation: Division of Haematology and Oncology, University of Alabama School of Medicine, 1720 2nd Avenue South, NP2540, Birmingham, Alabama 35294-3300, USA.
authors.forename: Andres
authors.initials: A
authors.lastname: Forero
authors.affiliation: Department of Haematology, Hôpital Claude Huriez, F-59037 Lille, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.affiliation: Department of Haematology, Academic Medical Center and LYMMCARE, Amsterdam, Netherlands.
authors.forename: Marie Jose
authors.initials: MJ
authors.lastname: Kersten
authors.affiliation: Haematology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.affiliation: Institute of Haematology "L. e A. Seràgnoli," University of Bologna, Via Massarenti, 9-40138 Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.affiliation: Massachusetts General Hospital Cancer Center, Yawkey Center for Outpatient Care, Mailstop: Yawkey 9A, 32 Fruit Street, Boston, Massachusetts 02114, USA.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Abramson
authors.affiliation: UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Vose
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D008223:Lymphoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors